| Date | Title | Description |
| 23.09.2025 | Forgent AI secures €4.3M to transform public procurement | Forgent AI, an AI company reinventing how businesses win public sector contracts, today announced it has raised €4.3 million in Pre-Seed funding.
Public procurement represents a €2 trillion market in Europe, yet tens of billions are lost an... |
| 22.05.2024 | LabGenius secures £35M Series B funding for therapeutic antibody discovery | LabGenius, a drug discovery company pioneering the use of machine learning for the discovery of novel therapeutic antibodies has closed a £35 million Series B financing round.
The investment brings LabGenius’ total funding to date to £58 mi... |
| 21.05.2024 | UK’s LabGenius secures €40.9M led by Amsterdam’s M Ventures to advance its drug discovery platform | Read this article in:
London-based LabGenius, a drug discovery company, announced that it has secured £35M (approximately €40.96M) in a Series B round of funding. The company specialises in using machine learning to discover new therapeutic... |
| 21.05.2024 | London-based LabGenius raises over €40.1 million to further develop its ML-driven antibody discovery platform | - |
| 21.05.2024 | LabGenius Raises £35M in Series B Funding | LabGenius, a London, UK-based drug discovery company, raised £35M in Series B funding.
The round was led by M Ventures (the strategic, corporate venture capital arm of science and technology company Merck), with participation from additiona... |
| 18.09.2023 | Questions every VC needs to ask about every AI startup’s tech stack | Leonard Wossnig Contributor
Share on X
Leonard Wossnig is the CTO of LabGenius and former founder and CEO of Rahko and VP of AI at Odyssey Therapeutics.
From fraud detection to agricultural crop monitoring, a new wave of tech startups has e... |
| 10.08.2023 | Using AI to find antibodies is fast and produces unimagined molecules | Enlarge / Researchers use CyBio FeliX workstations to extract and purify DNA samples for testing
LabGenius reader comments 64 with
At an old biscuit factory in South London, giant mixers and industrial ovens have been replaced by robotic ar... |
| 04.04.2023 | LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors | Prominent oncology clinician Prof Hendrik-Tobias Arkenau and computational antibody design expert Prof Victor Greiff will bolster LabGenius’ leadership in the field of machine learning-driven antibody discovery.
LONDON–(BUSINESS WIRE)–April... |
| 30.11.2022 | LabGenius Wins Government Innovation Grant to Support the Development of ML-driven Cancer Therapies | The UK’s innovation agency, Innovate UK, has awarded LabGenius Biomedical Catalyst funding to drive the development of their immunotherapy pipeline
LONDON–(BUSINESS WIRE)–November 30, 2022–
LabGenius, a pioneer in the use of machine learnin... |
| 16.11.2022 | LabGenius Appoints Dr. Leonard Wossnig as Chief Technology Officer | Rahko’s Co-founder and former VP of AI at Odyssey Therapeutics will lead the technical growth of LabGenius’ ML-driven drug discovery platform
LONDON–(BUSINESS WIRE)–November 16, 2022–
LabGenius, a pioneer in the use of machine learning (ML)... |
| 07.10.2022 | LabGenius Secures Government Innovation Grant to Expand ML-driven Drug Discovery Platform, EVA™ | Innovate UK, part of UK Research and Innovation (UKRI), has awarded LabGenius with a SMART grant to accelerate the development of its immune cell engager lead optimization capability
LONDON–(BUSINESS WIRE)–October 7, 2022–
LabGenius, a pion... |
| 29.11.2021 | LabGenius Appoints Dr. Gino Van Heeke as Chief Scientific Officer | With over 20 years of industry experience, the former Senior Director, Discovery and Early Development at Ablynx, will lead LabGenius’ drug discovery and pre-clinical development activities.
LONDON–(BUSINESS WIRE)–November 30, 2021–
LabGeni... |
| 21.09.2021 | LabGenius Appoints Dr. Didier Landais as Chief Operating Officer | With over 30 years of industry experience, the former Global Head of Licensing at Servier Group will spearhead LabGenius’ business development, commercial strategy, and operational delivery.
LONDON–(BUSINESS WIRE)–September 22, 2021–
LabGen... |
| 15.07.2021 | LabGenius Announces Research Collaboration With Ablynx, a Sanofi Company | Multi-year collaboration where LabGenius will apply its ML-driven protein engineering platform, EVATM, to the optimization of therapeutic NANOBODY® proteins
LONDON–(BUSINESS WIRE)–July 15, 2021–
LabGenius, a pioneer in the use of machine le... |
| 15.07.2021 | LabGenius Announces Research Collaboration With Ablynx, a Sanofi Company | Join executive leaders at the Conversational AI & Intelligent AI Assistants Summit, presented by Five9. Watch now!
Multi-year collaboration where LabGenius will apply its ML-driven protein engineering platform, EVATM, to the optimizatio... |
| 12.05.2021 | London-based LabGenius raises $3.66m seed funding for its ‘Silicon Scientist’, Eva | LabGenius, a London-based synthetic biology start-up, has raised $3.66m in an oversubscribed seed funding round.
The financing was jointly led by Kindred Capital and Acequia Capital with participation from Backed VC, Beast Ventures, Berggru... |
| 27.01.2021 | Ones to Watch in 2021: The 33 UK scaleups joining the prestigious Upscale programme | It is with great excitement that we introduce the 33 UK scaleups that have been selected to join Upscale 6.0. Upscale is one of our flagship growth programmes, focused on helping the fastest growing mid-stage tech companies in the UK to tac... |
| 30.10.2020 | This London-based startup uses AI and robotics to discover protein therapeutics; raises €12.8M | The growth in Artificial Intelligence (AI) technology integration is increasing rapidly in various sectors. A lot of startups across the world are creating new approaches and seeking innovative business models in a bid to disrupt the pharma... |
| 29.10.2020 | LabGenius closes $15 million Series A extension led by Atomico, brings round to $25 million | London-based LabGenius, a biotech company using machine learning to develop new therapeutics, has secured a $15 million extension of its Series A, bringing the round’s total to $25 million. Atomico led the investment, and partner Irina Haiv... |
| 24.10.2019 | LabGenius Raises $10M in Series A Funding | LabGenius, a London, UK-based developer of an AI driven drug discovery platform, raised $10m in Series A funding.
The round was led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, Inovia Capital, Gigafund, Air... |
| 23.10.2019 | Daily funding roundup - October 22nd, 2019 | Reibus raised $3.25M; AllWork landed $3.8M; MediView XR closed $4.5M; Beem picks up $5M
Bizly: Bizly is a modern enterprise SaaS platform that helps company teams build powerful events from start-to-finish and maximize the impact of every i... |
| 23.10.2019 | London-based LabGenius raises €11.5 million to scale its AI-driven drug discovery platform | LabGenius has announced today that it has raised over €11.5 million in its Series A funding round. Founded in 2012, LabGenius is a drug discovery company that is using artificial intelligence (AI), robotic automation, and synthetic biology ... |
| 23.10.2019 | LabGenius: London-based startup gets €11.5M for discovering next-gen drugs using AI | The growth in Artificial Intelligence (AI) has proliferated into various sectors. A lot of startups across the world are creating new approaches and seeking after the inventive business models in a bid to alter the pharmaceutical businesses... |
| 23.10.2019 | LabGenius raises $10m Series A | LabGenius has announced that it has raised over $10 million in its Series A financing round. LabGenius is a drug discovery company that is using artificial intelligence, robotic automation, and synthetic biology to discover novel protein th... |
| 22.10.2019 | LabGenius raises $10M to use AI for protein drug discovery | LabGenius, a London-based startup applying AI and “robotic automation” to protein drug discovery, has raised $10 million in Series A funding.
The round is led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, In... |
| 26.04.2019 | London-based LabGenius raises $3.66m seed funding for its ‘Silicon Scientist’, Eva | LabGenius, a London-based synthetic biology start-up, has raised $3.66m in an oversubscribed seed funding round.
The financing was jointly led by Kindred Capital and Acequia Capital with participation from Backed VC, Beast Ventures, Berggru... |
| 27.11.2017 | Term Sheet — Monday, November 27 | THE END OF AN ERA
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
Meredith Corp, which owns Better Homes & Gardens and Family Circle, agreed to buy Time Inc for $18.50 a shar... |
| 26.11.2017 | LabGenius Raises $3.66M in Seed Funding | LabGenius, a London, UK–based synthetic biology startup, raised $3.66m in seed funding.
The round was jointly led by Kindred Capital and Acequia Capital with participation from Backed VC, Beast Ventures, Berggruen Holdings, System.One, Char... |
| 24.11.2017 | UK synthetic biology startup LabGenius raises $3.66 million seed round | LabGenius, a London-based synthetic biology startup, has raised $3.66 million in seed funding led by Kindred Capital and Acequia Capital.
Other participants in the round include firms Berggruen Holdings, Backed VC, Beast Ventures, and Syste... |
| 19.11.2013 | Who are the Challenge Cup London’s Hottest Showcasing Startups? [POLL] | In case you missed it, Tech Cocktail has proudly partnered with 1776, the Washington, DC-based startup incubator, to bring you the Challenge Cup – a global competition to identify the hottest startups in education, energy, health, and smart... |
| - | London-based LabGenius raises $3.66m seed funding for its ‘Silicon Scientist’, Eva | LabGenius, a London-based synthetic biology start-up, has raised $3.66m in an oversubscribed seed funding round.
The financing was jointly led by Kindred Capital and Acequia Capital with participation from Backed VC, Beast Ventures, Berggru... |
| - | LabGenius | “At LabGenius, we're finding the next generation of antibody therapeutics with machine learning, synthetic biology and laboratory automation” |
